PT100524A - Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem - Google Patents

Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem

Info

Publication number
PT100524A
PT100524A PT100524A PT10052492A PT100524A PT 100524 A PT100524 A PT 100524A PT 100524 A PT100524 A PT 100524A PT 10052492 A PT10052492 A PT 10052492A PT 100524 A PT100524 A PT 100524A
Authority
PT
Portugal
Prior art keywords
pct
phospholipids
dha
epa
fatty acids
Prior art date
Application number
PT100524A
Other languages
English (en)
Other versions
PT100524B (pt
Inventor
Carin Larsson-Backstrom
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of PT100524A publication Critical patent/PT100524A/pt
Publication of PT100524B publication Critical patent/PT100524B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT100524A 1991-05-30 1992-05-27 Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem PT100524B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101642A SE9101642D0 (sv) 1991-05-30 1991-05-30 Phospholipids

Publications (2)

Publication Number Publication Date
PT100524A true PT100524A (pt) 1993-08-31
PT100524B PT100524B (pt) 1999-08-31

Family

ID=20382886

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100524A PT100524B (pt) 1991-05-30 1992-05-27 Emulsoes aquosas de oleos de origem vegetal e/ou marinha contendo fosfolipidos e composicoes que as contem

Country Status (14)

Country Link
US (1) US5434183A (pt)
EP (1) EP0660708B1 (pt)
JP (1) JP3387498B2 (pt)
AT (1) ATE216227T1 (pt)
AU (1) AU657969B2 (pt)
CA (1) CA2109611A1 (pt)
DE (1) DE69232564T2 (pt)
ES (1) ES2174833T3 (pt)
IE (1) IE921477A1 (pt)
NZ (1) NZ242697A (pt)
PT (1) PT100524B (pt)
SE (1) SE9101642D0 (pt)
SG (1) SG64864A1 (pt)
WO (1) WO1992021335A1 (pt)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
WO1994022313A1 (en) * 1993-04-01 1994-10-13 Ici Australia Operations Proprietary Limited Pan release agent
WO1994028732A1 (en) * 1993-06-07 1994-12-22 Ici Australia Operations Proprietary Limited Reduction of moisture loss from plant and animal matter
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ATE167983T1 (de) * 1994-10-05 1998-07-15 Milupa Gmbh & Co Kg Phospholipidhaltige fettmischung mit lcp- fettsäuren
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JP2000501131A (ja) * 1995-11-24 2000-02-02 ロダース・クロックラーン・ビー・ブイ 魚油をベースとする組成物
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
DE19644518A1 (de) * 1996-10-25 1998-04-30 Nutricia Nv Wässrige Fettemulsion, diese enthaltende Nahrung und deren Verwendung
US6344482B1 (en) * 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) * 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US5955102A (en) 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
CO5111023A1 (es) 1998-12-31 2001-12-26 Kimberly Clark Co Composicion de articulo absorbente y metodo para usarla para secuestrar irritantes de la piel
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
AU2001264079A1 (en) * 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
EP1539104A2 (en) * 2000-12-29 2005-06-15 The Trustees Of Columbia University In The City Of New York Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
AU2002319961A1 (en) * 2001-07-27 2003-02-17 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1417211B1 (en) 2001-07-27 2007-05-30 Neptune Technologies & Bioressources Inc. Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses
AU2002323409A1 (en) * 2001-08-24 2003-03-10 Martek Biosciences Boulder Corporation Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum
BR0308290A (pt) * 2002-03-08 2005-01-11 Monsanto Technology Llc Tratamento e prevenção de distúrbios inflamatórios
WO2004047554A1 (en) * 2002-11-26 2004-06-10 Phares Pharmaceutical Research N.V. Marine lipid compositions
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
EP1684739A4 (en) * 2003-11-12 2006-12-06 Childrens Medical Center TREATMENT AND PREVENTION OF LIVER DISEASES RELATED TO PARENTERAL DIET (PN)
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
WO2005122795A1 (en) * 2004-06-10 2005-12-29 Kellogg Company Topical application of marine oils to foods
RU2351153C2 (ru) * 2004-07-01 2009-04-10 Нестек С.А. Композиция диеты при остеоартрите собак
EP1811867A2 (en) * 2004-11-12 2007-08-01 N.V. Nutricia Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses
FR2880538B1 (fr) * 2005-01-07 2008-12-26 Polaris Soc Par Actions Simpli Composition cosmetique et cosmeceutique a base d'huiles de poissons, de phospholipides d'origine marine avec ou sans huile de pepins de franboise
GB0506788D0 (en) * 2005-04-04 2005-05-11 Biosea Man As Process
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP3263101A1 (en) * 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods
WO2008149177A2 (en) * 2006-05-05 2008-12-11 Natural Asa Marine lipid compositions and uses thereof
US20080044487A1 (en) 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
WO2008143642A2 (en) * 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
WO2008070467A2 (en) * 2006-12-01 2008-06-12 Joseph Thomas Weishaar Method for preventing chronic disease
EP2120912B1 (en) 2007-02-15 2013-04-03 Chu Sainte-justine Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2144618B2 (en) * 2007-03-28 2024-11-20 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US20100075333A1 (en) * 2007-03-30 2010-03-25 Alain Moreau Method of determining the risk of scoliosis
JP5443979B2 (ja) * 2007-05-11 2014-03-19 備前化成株式会社 新規のロイコトリエン受容体アンタゴニスト
WO2009027692A2 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa A new method for making krill meal
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NO2493478T3 (pt) 2009-10-29 2018-07-21
US8974818B2 (en) * 2010-01-20 2015-03-10 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
RS56394B1 (sr) * 2011-06-15 2017-12-29 Stable Solutions Llc Terapeutska primena parenteralnog kril ulja
US10383839B2 (en) 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150110866A1 (en) * 2012-05-22 2015-04-23 Harold Gordon Cave Complexes and compositions containing curcumin
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CA2883997C (en) 2012-08-29 2021-02-16 Universite Du Quebec A Chicoutimi Dihydrochalcone derivatives and their use as antibiotic agents
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
WO2014201557A1 (en) 2013-06-17 2014-12-24 Chu Ste-Justine Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects
AU2014284078A1 (en) 2013-06-17 2016-01-07 Chu Sainte-Justine New markers for severe progression of idiopathic scoliosis and uses thereof to stratify scoliotic patients and predict the risk of developing scoliosis
CN105377298B (zh) 2013-06-17 2020-04-10 圣-贾斯汀大学中心医院 一种增加脊柱侧凸受试者的细胞中的gipcr信号传导作用的方法
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
CA2918291C (en) 2013-07-22 2022-12-06 Universite Du Quebec A Chicoutimi Use of plant extracts against herpes simplex virus
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3200606B1 (de) 2014-10-02 2021-03-31 Evonik Operations GmbH Verfahren zur herstellung eines pufas enthaltenden futtermittels durch extrusion einer pufas enthaltenden biomasse des typs labyrinthulomycetes
BR112017006838B1 (pt) 2014-10-02 2021-07-06 Evonik Operations Gmbh Processo para produzir um alimento para animais compreendendo biomassa contendo pufa, alimento para animais e método para criar animais
US11464244B2 (en) 2014-10-02 2022-10-11 Evonik Operations Gmbh Feedstuff of high abrasion resistance and good stability in water, containing PUFAs
EP3200604B2 (de) 2014-10-02 2025-05-07 Evonik Operations GmbH Verfahren zur herstellung eines futtermittels
CN114304375A (zh) 2015-02-11 2022-04-12 阿克海洋生物南极股份公司 脂质组合物
PT3256003T (pt) 2015-02-11 2023-02-15 Aker Biomarine Antarctic As Processo de extração de lipídios
US20180051230A1 (en) * 2015-03-19 2018-02-22 Arctic Nutrition As Methods for obtaining phospholipids and compositions thereof
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11773129B2 (en) 2017-05-25 2023-10-03 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
PT3664628T (pt) 2017-08-10 2024-12-31 Childrens Medical Ct Corp Métodos e composições relacionados com emulsões compreendendo óleo de peixe e/ou ácidos gordos ómega-3
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN109527123A (zh) * 2018-12-14 2019-03-29 大连大学 一种对慢性肠炎具有改善作用的调和油
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US20240081374A1 (en) 2022-09-14 2024-03-14 Société des Produits Nestlé S.A. Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT333437B (de) * 1974-02-07 1976-11-25 Etapharm Chem Pharm Lab Ges M Verfahren zur herstellung von phosphatidkomplexen mit erhohtem phosphatidylathanolamingehalt aus tierischem material
DE3347269A1 (de) * 1983-12-28 1985-07-11 Pearson & Co (GmbH & Co), 5000 Köln Pharmazeutisch wirksame lecithine mit polyungesaettigten fettsaeuren
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
SG64864A1 (en) 2001-01-16
CA2109611A1 (en) 1992-12-10
JPH06508123A (ja) 1994-09-14
NZ242697A (en) 1994-02-25
SE9101642D0 (sv) 1991-05-30
EP0660708B1 (en) 2002-04-17
PT100524B (pt) 1999-08-31
EP0660708A1 (en) 1995-07-05
WO1992021335A1 (en) 1992-12-10
AU657969B2 (en) 1995-03-30
US5434183A (en) 1995-07-18
ATE216227T1 (de) 2002-05-15
IE921477A1 (en) 1992-12-02
DE69232564D1 (de) 2002-05-23
ES2174833T3 (es) 2002-11-16
AU1910192A (en) 1993-01-08
DE69232564T2 (de) 2002-09-26
JP3387498B2 (ja) 2003-03-17

Similar Documents

Publication Publication Date Title
ES2174833T3 (es) Fosfolipidos.
ES2173673T3 (es) Mezcla grasa y agentes dieteticos o farmaceuticos que las contienen.
AU616713B2 (en) Use of fatty acids against cyclosporin side effects
KR880008797A (ko) 실리마린이 포함된 피부미용용 조성물
Freese et al. Comparison of the effects of two diets rich in monounsaturated fatty acids differing in their linoleic/α-linolenic acid ratio on platelet aggregation
Place Comparative aspects of lipid digestion and absorption: physiological correlates of wax ester digestion
Kalogeris et al. Intestinal synthesis and lymphatic secretion of apolipoprotein A–IV vary with chain length of intestinally infused fatty acids in rats
KR940018090A (ko) 트리글리세라이드
EP1072249A3 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
CA2189202A1 (en) Stable Edible Oil Composition
JPS57110176A (en) Nutrious food composition for tube feeding
KR840005339A (ko) 지용성물질을 함유한 수용액의 제조방법
Hamazaki et al. Administration of docosahexaenoic acid influences behavior and plasma catecholamine levels at times of psychological stress
NO952185D0 (no) Pai-skall
CA2124605A1 (en) Prevention and improvement of medical symptoms caused by leucotriene b4
DK0456764T3 (da) Omega-3-fedtsyreholdig fedtemulsion til endotracheal indgift, fremstilling og anvendelse heraf
DE68926527D1 (de) Essbarer Aufstrich
OKITA et al. N-3 and n-6 fatty acid intake and serum phospholipid fatty acid composition in middle-aged women living in rural and urban areas in Okayama Prefecture
IES940674A2 (en) "An edible fat blend containing fish oil"
NO950621L (no) Fiskefor
US20110218151A1 (en) Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate
Rao et al. Dietary carbohydrate stimulates alcohol diet ingestion, promotes growth and prevents fatty liver in rats
Reiser et al. The glyceride structure of swine depot fat

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930331

FG3A Patent granted, date of granting

Effective date: 19990526

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001130